Origin study insulin glargine
WitrynaORIGIN (Outcome Reduction with Initial Glargine Intervention), a long-term international clinical trial conducted on 12,537 people in 40 countries, over a period of six years, assessed the effect of therapy with basal insulin (supplied as insulin glargine) … Witryna13 sie 2013 · For the insulin glargine arm of the study, we observed a statistically nonsignificant reduction in CIMT progression for the primary outcome and significant differences, favoring insulin glargine therapy for the secondary CIMT outcomes. ... Our findings provide further data supporting the CV safety of insulin glargine. The parent …
Origin study insulin glargine
Did you know?
Witryna11 maj 2024 · Insulin Glargine is a man-made insulin, which is very similar to human insulin. It has a long and steady (constant) effect on the blood sugar levels and the action lasts for an entire day. This makes it suitable to be used once daily. It is used to treat type 2 diabetes mellitus in adults and type 1 diabetes mellitus in adults and … Witryna13 cze 2024 · Study Description Go to Brief Summary: The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar levels. Side effects and tolerability will be documented.
Witryna11 cze 2012 · insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Al-though it reduced new-onset diabetes, insulin glargine also increased … WitrynaNational Center for Biotechnology Information
Witryna26 lip 2012 · To the Editor: In their report on the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) study, Gerstein et al. (July 26 issue) 1 conclude that … WitrynaBackgroundDegludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies …
Witryna23 paź 2024 · The ORIGIN trial suggests at least a neutral effect of the basal insulin glargine on cardiovascular outcomes. Recent studies have demonstrated that ultra-long-acting insulin analogs like insulin degludec are non-inferior to insulin glargine with regard to cardiovascular outcomes. Introduction
Witryna11 cze 2012 · Second, the ORIGIN trial involved people who are not normally prescribed insulin and in whom insulin glargine was used to achieve fasting plasma glucose … irish electricWitrynaChronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study In high-risk patients with dysglycemia (prediabetes … irish election results historyWitryna1 gru 2024 · The Outcome Reduction with an Initial Glargine Intervention (ORIGIN trial) of dysglycemic participants with either prediabetes or early type 2 diabetes (of … irish electric nhWitryna1 sty 2012 · This trial sought to study if early normalization of fasting glucose levels by early provision of basal insulin in patients with impaired fasting glucose (IFG), … porsche suv top speedWitryna28 paź 2014 · Hypoglycemia is a leading risk of glucose-lowering therapy. Treatment with insulin glargine compared with standard care early in the course of dysglycemia in the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial provides information on the frequency and predictors of hypoglycemia in this setting. irish electronic componentsWitryna26 kwi 2014 · Study participants provided written informed consent, with the study approved by the ethics committee at each study site. ORIGIN intervention with insulin glargine. As described in detail previously , participants assigned to the insulin glargine group added an evening injection to their pre-existing anti-hyperglycaemic regimen, … porsche suv taxiWitrynaThe landmark ORIGIN trial provides many lessons relating to the concept and application of early insulin therapy for the prevention and safe and effective induction and … porsche suv with 3rd row